Abstract
The aim of the present study is to develop and formulate a nanoparticulate carrier for sustained and ocular delivery of Fluconazole and to study its in-vitro release characters. Chitosan nanoparticles of Fluconazole were formulated by spontaneous emulsification and cross-linking method. The mean particle size, drug loading capacity, invitro release profile and release kinetics were studied. The antifungal efficacies of nanospheres were compared with conventional eye drops by cup-plate method. The average particle size was found to be 152.85±13.7nm. The drug loading capacity of all drug loaded nanoparticles was found to be optimum (≤50%). The in-vitro release study revealed the zero order kinetics and Higuchi’s diffusion mechanism. The drug bound nanoparticles exhibited good in-vitro antifungal effect in comparison with conventional eye drops. The formulated nanoparticles were found to be a suitable carrier for sustained ocular delivery of Fluconazole in terms of optimum drug loading, sustained release characters and antifungal activity.
Keywords: Chitosan, fluconazole, nanoparticles, ocular, sustained release.
Nanoscience & Nanotechnology-Asia
Title:In-vitro Characterization of Chitosan Nanoparticles of Fluconazole as a Carrier for Sustained Ocular Delivery
Volume: 7 Issue: 1
Author(s): Kumaraswamy Santhi, Selvadurai Muralidharan, Young H. Yee, Fong Y. Min, Chong Z. Ting and Durga Devi
Affiliation:
Keywords: Chitosan, fluconazole, nanoparticles, ocular, sustained release.
Abstract: The aim of the present study is to develop and formulate a nanoparticulate carrier for sustained and ocular delivery of Fluconazole and to study its in-vitro release characters. Chitosan nanoparticles of Fluconazole were formulated by spontaneous emulsification and cross-linking method. The mean particle size, drug loading capacity, invitro release profile and release kinetics were studied. The antifungal efficacies of nanospheres were compared with conventional eye drops by cup-plate method. The average particle size was found to be 152.85±13.7nm. The drug loading capacity of all drug loaded nanoparticles was found to be optimum (≤50%). The in-vitro release study revealed the zero order kinetics and Higuchi’s diffusion mechanism. The drug bound nanoparticles exhibited good in-vitro antifungal effect in comparison with conventional eye drops. The formulated nanoparticles were found to be a suitable carrier for sustained ocular delivery of Fluconazole in terms of optimum drug loading, sustained release characters and antifungal activity.
Export Options
About this article
Cite this article as:
Santhi Kumaraswamy, Muralidharan Selvadurai, Yee H. Young, Min Y. Fong, Ting Z. Chong and Devi Durga, In-vitro Characterization of Chitosan Nanoparticles of Fluconazole as a Carrier for Sustained Ocular Delivery, Nanoscience & Nanotechnology-Asia 2017; 7 (1) . https://dx.doi.org/10.2174/2210681206666160402003316
DOI https://dx.doi.org/10.2174/2210681206666160402003316 |
Print ISSN 2210-6812 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6820 |
Call for Papers in Thematic Issues
Nanotechnology for Energy Harness and Material Development
The energy industry is one of the many that is being revolutionized by nanotechnology. There is great hope for the commercialization of these breakthroughs since they have the potential to make energy production safer, far more sustainable, greater efficient, and less expensive. Nanotechnology is being studied for its potential to ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Estrogen in the Brain: Is it a Neuroprotective Agent in Alzheimers Disease?
Current Aging Science Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications
Current Neuropharmacology Multiple Roles of Fibroblast Growth Factor 21 in Metabolism
Current Pharmaceutical Design Brain and Gut CRF Signaling: Biological Actions and Role in the Gastrointestinal Tract
Current Molecular Pharmacology Pharmaceutical Drug Nanocrystals: Role in Dermal Delivery
Nanoscience & Nanotechnology-Asia Von Willebrand Factor and Thrombosis: Risk Factor, Actor and Pharmacological Target
Current Vascular Pharmacology Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets ADAM28 as a Target for Human Cancers
Current Pharmaceutical Design The Use of N-Acetylcysteine in Respiratory Diseases
Current Respiratory Medicine Reviews Pivotal Role of the Genital Epithelial Cells in HIV-1 Transmission
Current HIV Research Impact of Omega-3 and Trans Fatty Acids on Vascular Remodeling:Opposing Roles in Cardiovascular Health
Current Enzyme Inhibition GEMSP: A New Therapeutic Approach to Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Designing of Selective γ-Secretase Inhibitory Benzenesulfonamides through Comparative In Vitro and In Silico Analysis
Current Drug Discovery Technologies Novel Functionalization for Maximizing Cell Turnover from Microcarrier
Current Biotechnology Morphologic and Molecular Backgrounds for Personalized Management of Genito-Urinary Cancers: An Overview
Current Drug Targets Gene Therapy Strategies to Prevent Autoimmune Disorders
Current Gene Therapy Synthesis of Salinosporamide A and Its Analogs as 20S Proteasome Inhibitors and SAR Summarization
Current Topics in Medicinal Chemistry Improvement of Adoptive Cellular Immunotherapy of Human Cancer Using Ex-Vivo Gene Transfer
Current Gene Therapy Bacterial Translocation, Microcirculation Injury and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Neuropeptides as Possible Targets in Sleep Disorders: Special Emphasis on Hypocretin-Deficient Narcolepsy
CNS & Neurological Disorders - Drug Targets